← All trials
NCT04760236
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 20, 2021
- Primary completion
- Jun 5, 2022
- Completion date
- Sep 20, 2022
- First posted
- Feb 18, 2021
- Last posted
- Feb 18, 2021
- Enrollment
- 2530
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- International Vaccine InstituteLead sponsor
- EuBiologics Co.,LtdCollaborator
- International Vaccine InstituteOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.